




Searching News Database: Micromet
HSMN NewsFeed - 3 Apr 2018
Oncternal Therapeutics Further Strengthens Leadership with Additions to Board of Directors
Oncternal Therapeutics Further Strengthens Leadership with Additions to Board of Directors
HSMN NewsFeed - 17 Jul 2017
Sensome, Formerly Instent, Raises €4.7m to Bring the World's First Connected Stroke Guidewire to Patients
Sensome, Formerly Instent, Raises €4.7m to Bring the World's First Connected Stroke Guidewire to Patients
HSMN NewsFeed - 25 Sep 2015
Surefire Medical Launches Advanced Precision Direct-To-Tumor Infusion System At CIRSE
Surefire Medical Launches Advanced Precision Direct-To-Tumor Infusion System At CIRSE
HSMN NewsFeed - 28 Oct 2014
Advent Life Sciences Raises £145.5M (USD 235M) for its Second Life Sciences Venture Capital Fund
Advent Life Sciences Raises £145.5M (USD 235M) for its Second Life Sciences Venture Capital Fund
HSMN NewsFeed - 21 Aug 2014
Galena Biopharma Appoints Mark W. Schwartz, Ph.D., as President and Chief Executive Officer
Galena Biopharma Appoints Mark W. Schwartz, Ph.D., as President and Chief Executive Officer
HSMN NewsFeed - 19 Dec 2013
Celator(R) Pharmaceuticals Appoints Joseph M. Lobacki to Board of Directors
Celator(R) Pharmaceuticals Appoints Joseph M. Lobacki to Board of Directors
HSMN NewsFeed - 4 Dec 2012
Galena Biopharma Announces Signature of Commercialization Partnership With Teva for Israel
Galena Biopharma Announces Signature of Commercialization Partnership With Teva for Israel
HSMN NewsFeed - 9 Oct 2012
Cytos Biotechnology Ltd appoints Dr. Christian Itin as Chief Executive Officer
Cytos Biotechnology Ltd appoints Dr. Christian Itin as Chief Executive Officer
HSMN NewsFeed - 30 Jul 2012
Biovest Advances Process Seeking European Marketing Approval for BiovaxID(TM) Personalized Lymphoma Vaccine
Biovest Advances Process Seeking European Marketing Approval for BiovaxID(TM) Personalized Lymphoma Vaccine
HSMN NewsFeed - 24 Apr 2012
Nordion Announces Europe-Focused Phase III Clinical Trial for TheraSphere(R) Liver Cancer Treatment
Nordion Announces Europe-Focused Phase III Clinical Trial for TheraSphere(R) Liver Cancer Treatment
HSMN NewsFeed - 28 Mar 2012
Kapil Dhingra, Former Head of Roche Oncology, Joins Exosome Diagnostics Board of Directors
Kapil Dhingra, Former Head of Roche Oncology, Joins Exosome Diagnostics Board of Directors
HSMN NewsFeed - 5 Dec 2011
Micromet Appoints Joseph Lobacki Senior Vice President and Chief Commercial Officer
Micromet Appoints Joseph Lobacki Senior Vice President and Chief Commercial Officer
HSMN NewsFeed - 14 Jun 2011
Micromet Appoints Ulrich Grau, Ph.D. Executive Vice President and Chief Operating Officer
Micromet Appoints Ulrich Grau, Ph.D. Executive Vice President and Chief Operating Officer
HSMN NewsFeed - 21 Jan 2010
Genomic Health Announces Worldwide Availability of the Oncotype DX(R) Colon Cancer Test
Genomic Health Announces Worldwide Availability of the Oncotype DX(R) Colon Cancer Test
HSMN NewsFeed - 22 Sep 2009
Micromet Appoints Former Roche Oncology Clinical Leader Jan Fagerberg as Chief Medical Officer
Micromet Appoints Former Roche Oncology Clinical Leader Jan Fagerberg as Chief Medical Officer
HSMN NewsFeed - 23 Feb 2009
Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
HSMN NewsFeed - 8 Oct 2008
Calistoga Pharmaceuticals Appoints Carol G. Gallagher, Pharm. D., Chief Executive Officer
Calistoga Pharmaceuticals Appoints Carol G. Gallagher, Pharm. D., Chief Executive Officer
HSMN NewsFeed - 4 Dec 2007
VistaGen Names Agustin de la Calle, Ph.D. as Vice President, Business Development
VistaGen Names Agustin de la Calle, Ph.D. as Vice President, Business Development
HSMN NewsFeed - 12 Sep 2007
Micromet Appoints Mark Reisenauer as Senior Vice President and Chief Commercial Officer
Micromet Appoints Mark Reisenauer as Senior Vice President and Chief Commercial Officer
HSMN NewsFeed - 12 Feb 2007
Morphotek Obtains Exclusive License from Micromet for Antibody to Treat Melanoma and Other Cancers
Morphotek Obtains Exclusive License from Micromet for Antibody to Treat Melanoma and Other Cancers
HSMN NewsFeed - 5 Dec 2006
Micromet, Inc. and Serono Amend Collaboration Agreement and Continue Development of Adecatumumab (MT201)
Micromet, Inc. and Serono Amend Collaboration Agreement and Continue Development of Adecatumumab (MT201)
Additional items found! 19

Members Archive contains
19 additional stories matching:
Micromet
(Password required)
Micromet
(Password required)